DVAX Stock Cash Flow Statements

Dynavax Technologies Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Dynavax Technologies Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30

operating activities
net income	18,721,000	-96,099,000	7,050,000	17,594,000	11,386,000	-8,721,000	219,000	14,293,000	3,431,000	-24,332,000	67,733,000	63,809,000	128,755,000	32,859,000	99,779,000	-28,430,000	4,473,000	891,000	-15,467,000	4,401,000	-51,579,000	-12,595,000	-36,756,000	-33,459,000	-42,713,000	-39,672,000	-39,969,000	-40,528,000	-39,444,000	-38,958,000	-27,421,000	-22,128,000	-20,318,000	-25,287,000	-21,741,000	-34,694,000	-28,986,000	-27,023,000	-26,862,000	-30,124,000	-23,591,000	-26,217,000	-22,286,000	-29,819,000	-24,777,000	-13,840,000	-13,056,000	-15,675,000	-17,164,000	-20,825,000	-20,543,000	-17,791,000	-15,110,000	-16,505,000		-15,229,000	-10,635,000	-18,466,000									3,099,000	-5,420,000	-6,079,000	-12,429,000	-12,076,000	-17,101,000	-17,704,000	-13,090,000	-16,455,000	-12,152,000	-15,273,000	-8,172,000	-8,762,000	-8,284,000	-8,579,000	5,070,000	-5,163,000	-4,033,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	1,242,000	1,173,000	1,184,000	1,184,000	1,135,000	1,124,000	1,114,000	1,115,000	1,100,000	1,013,000	837,000	890,000	1,100,000	985,000	1,016,000	1,078,000	1,096,000	1,106,000	1,107,000	1,103,000	1,049,000	1,014,000	1,100,000	4,642,000	1,494,000	1,702,000	1,110,000	853,000	835,000	823,000	788,000	782,000	885,000	789,000	683,000	628,000	544,000	402,000	407,000	324,000	299,000	335,000	388,000	336,000	341,000	339,000	341,000	340,000	327,000	319,000	309,000	306,000	300,000	292,000	294,000	305,000	344,000	360,000	301,000	343,000	372,000	399,000	422,000	475,000	490,000	470,000	489,000	453,000	470,000	438,000	392,000	379,000	371,000	341,000	333,000	1,624,000	-1,011,000	184,000	181,000	191,000	203,000	184,000	229,000	97,000
amortization of right-of-use assets	797,000	863,000	887,000	870,000	844,000	824,000									702,000	687,000	673,000	653,000	656,000	645,000	627,000	634,000	633,000	696,000	744,000	1,302,000
inventory write off	0	3,976,000		0	0	1,264,000
sublease termination loss			49,000	0	0	4,765,000
accretion of discounts on marketable securities	-1,698,000	-2,137,000		-3,427,000	-3,937,000	-4,528,000		-4,050,000	-3,765,000	-3,498,000											9,000	-87,000		-418,000	-552,000	-323,000		-465,000	-505,000	-176,000
stock-based compensation expense	12,979,000	14,455,000	13,004,000	13,083,000	13,518,000	13,014,000	11,309,000	10,687,000	10,562,000	10,034,000																																		1,586,000	1,676,000	1,270,000						1,903,000	2,069,000	2,322,000		1,287,000	1,167,000	1,480,000		586,000	425,000	541,000	933,000	916,000	667,000	519,000	717,000	1,052,000	775,000	661,000	1,049,000	985,000	689,000	808,000	917,000	970,000
bad debt expense	0	10,970,000					0	0	0	12,313,000
non-cash interest expense	1,642,000	1,691,000	-1,116,000	1,698,000	-1,121,000	1,695,000	-1,126,000	1,690,000	-1,130,000	1,686,000	-1,134,000	1,682,000	-1,140,000	1,680,000	-938,000			414,000	413,000	403,000	388,000	1,338,000	1,440,000	1,398,000	1,321,000	814,000	811,000	805,000	791,000	348,000
loss on debt extinguishment	0	82,095,000													0	0
changes in operating assets and liabilities:
accounts and other receivables	-16,788,000	-9,651,000	28,371,000	-12,647,000	-16,476,000	-1,621,000	2,333,000	-1,513,000	12,112,000	30,336,000	-16,397,000	43,124,000	-37,306,000	-5,120,000	68,546,000	-94,462,000	-21,906,000	-61,333,000	8,362,000	-30,120,000	7,232,000	751,000	-64,000	-1,240,000	-1,791,000	-2,087,000	-2,197,000	-203,000	-541,000	91,000	-71,000	27,000	655,000	-123,000	948,000	-426,000
inventories	-1,284,000	-8,325,000	-9,533,000	60,000	-656,000	-9,780,000	-5,526,000	3,077,000	4,605,000	1,753,000	23,360,000	-43,115,000	5,059,000	-17,703,000	3,374,000	19,154,000	-17,605,000	-5,157,000	-4,656,000	-4,641,000	-6,293,000	-6,767,000	-1,976,000	-2,727,000	-9,060,000	-8,547,000	-6,570,000	-7,340,000	-4,562,000	-238,000
prepaid expenses and other current assets	-77,000	-5,518,000	-467,000	3,647,000	-1,490,000	-4,800,000	-23,000	-1,478,000	-1,868,000	-1,304,000	14,375,000	34,534,000	-51,543,000	-9,231,000	-12,671,000	-51,640,000	-76,000	-171,000	9,580,000	-9,323,000	-1,083,000	-1,000,000	-1,669,000	1,034,000	-797,000	154,000	-1,498,000	-721,000	-580,000	394,000	11,000	-199,000	-1,603,000	-39,000	-244,000	600,000	505,000	-301,000	62,000	1,369,000	-380,000	580,000	-480,000	1,400,000	-2,655,000	-948,000	-255,000	121,000	-24,000	835,000	367,000	1,726,000	-2,277,000	-738,000	263,000	395,000	-273,000	-155,000	-281,000	-262,000	-15,000	-216,000	422,000	223,000	-133,000	-107,000	360,000	262,000	67,000	844,000	-111,000	-653,000	-78,000	-1,009,000	444,000	158,000	1,429,000	-1,427,000		330,000	-19,000	-721,000		-113,000
accounts payable	-1,835,000	-4,668,000	1,876,000	2,592,000	2,071,000	-2,640,000	2,564,000	-461,000	-4,247,000	4,096,000	390,000	-2,018,000	-14,619,000	16,938,000	-222,000	-7,754,000	7,504,000	-295,000	-2,015,000	2,560,000	-1,898,000	-2,095,000	1,813,000	218,000	-1,607,000	4,424,000	1,040,000	754,000	1,274,000	349,000	-416,000	1,435,000	-824,000	-2,110,000	477,000	-900,000	946,000	658,000	973,000	-375,000	-1,395,000	2,043,000	-3,807,000	3,172,000	-42,000	154,000	220,000	36,000	-474,000	-439,000	588,000	423,000	-1,203,000	318,000	727,000	-429,000	-138,000	-449,000	262,000	1,034,000	-58,000	-595,000	649,000	-185,000	134,000	183,000	-225,000	-249,000	-1,385,000	-1,654,000	2,467,000	-1,454,000	1,841,000	-617,000	-927,000	1,691,000	248,000	-6,000		639,000	891,000	-662,000		-102,000
lease liabilities	-1,051,000	-1,101,000	-1,167,000	-1,111,000	-1,084,000	-1,025,000	-994,000	-956,000	-886,000	-793,000	-759,000	-688,000	-872,000	-806,000	-818,000	-862,000	-803,000	-751,000	-741,000	-748,000	-711,000	-672,000	-660,000	-579,000	-655,000	-106,000
accrued and other liabilities	10,783,000	-7,363,000	7,065,000	3,594,000	6,742,000	-6,368,000
net cash from operating activities	23,431,000	-19,639,000	53,011,000	19,467,000	10,713,000	-16,679,000	13,766,000	31,129,000	28,046,000	27,622,000	34,948,000	61,560,000	16,651,000	-50,443,000	120,497,000	66,211,000	110,788,000	38,032,000	-15,743,000	-27,821,000	-21,821,000	-26,866,000	-23,012,000	-21,977,000	-36,361,000	-39,902,000	-33,630,000	-33,872,000	-33,927,000	-29,872,000	-17,749,000	-17,127,000	-17,392,000	-25,250,000	-26,282,000	-28,208,000	-25,427,000	-27,134,000	-21,846,000	-23,002,000	-23,572,000	-24,139,000	-16,867,000	-23,089,000	-22,606,000	-11,176,000	-11,843,000	-12,255,000	-15,689,000	-18,886,000	-7,592,000	-12,347,000	-15,689,000	-8,181,000	-5,288,000	-12,704,000	-9,629,000	-19,495,000	-17,886,000	-12,189,000	-13,793,000	-7,502,000	-9,291,000	-8,842,000	-7,372,000	-8,047,000	3,981,000	1,974,000	-8,725,000	-14,265,000	18,429,000	-17,104,000	-18,458,000	-14,899,000	-17,681,000	-1,644,000	-10,381,000	-7,534,000	-8,495,000	-7,614,000	1,307,000	-8,056,000	-5,306,000	-999,000
capex	-1,798,000	-1,882,000	-2,517,000	-1,158,000	-560,000	-394,000	-2,128,000	-183,000	-1,137,000	-357,000	-1,545,000	-1,522,000	-3,706,000	649,000	-4,006,000	-4,199,000	655,000	-1,336,000	-772,000	-25,000	-970,000	-1,944,000	-2,268,000	-12,972,000	-7,501,000	-3,882,000	-1,349,000	-1,199,000	-742,000	-897,000	-295,000	-132,000	-8,000	-234,000	-1,241,000	-1,600,000	-2,305,000	-2,611,000	-2,724,000	-2,578,000	-1,050,000	-618,000	0	-288,000	-521,000	-398,000	-313,000	-488,000	-293,000	-535,000	-1,204,000	-324,000	-471,000	-932,000	-564,000	-159,000	-278,000	-141,000	-287,000	-94,000	-433,000	394,000	71,000	-378,000	-505,000	435,000	230,000	444,000	-1,374,000	-3,398,000	0	0	0	-711,000	-647,000	0	0	-39,000	-110,000	-89,000	-282,000	-81,000	-209,000	-1,190,000
free cash flows	21,633,000	-21,521,000	50,494,000	18,309,000	10,153,000	-17,073,000	11,638,000	30,946,000	26,909,000	27,265,000	33,403,000	60,038,000	12,945,000	-49,794,000	116,491,000	62,012,000	111,443,000	36,696,000	-16,515,000	-27,846,000	-22,791,000	-28,810,000	-25,280,000	-34,949,000	-43,862,000	-43,784,000	-34,979,000	-35,071,000	-34,669,000	-30,769,000	-18,044,000	-17,259,000	-17,400,000	-25,484,000	-27,523,000	-29,808,000	-27,732,000	-29,745,000	-24,570,000	-25,580,000	-24,622,000	-24,757,000	-16,867,000	-23,377,000	-23,127,000	-11,574,000	-12,156,000	-12,743,000	-15,982,000	-19,421,000	-8,796,000	-12,671,000	-16,160,000	-9,113,000	-5,852,000	-12,863,000	-9,907,000	-19,636,000	-18,173,000	-12,283,000	-14,226,000	-7,108,000	-9,220,000	-9,220,000	-7,877,000	-7,612,000	4,211,000	2,418,000	-10,099,000	-17,663,000	18,429,000	-17,104,000	-18,458,000	-15,610,000	-18,328,000	-1,644,000	-10,381,000	-7,573,000	-8,605,000	-7,703,000	1,025,000	-8,137,000	-5,515,000	-2,189,000
investing activities
purchases of marketable securities	-18,096,000	-93,697,000	-33,016,000	-164,926,000	-175,436,000	-150,685,000	-152,881,000	-224,509,000	-74,230,000	-185,301,000	-117,630,000	-201,016,000	-63,285,000	-250,375,000	-1,000	1,000	-92,912,000	-72,016,000	-29,804,000	-68,800,000	-85,197,000	-17,985,000	-34,043,000	-72,807,000	-79,136,000	-29,205,000	-25,996,000	-987,000	-45,718,000	-141,103,000	-34,988,000	-99,639,000	-48,393,000	-44,652,000	-4,727,000	-23,919,000	-37,051,000	-61,057,000	-81,018,000	-109,264,000	0	-18,654,000	0	-7,556,000	-23,432,000	-13,819,000	-143,471,000	-19,046,000	-16,073,000	-13,454,000	-36,515,000	-55,234,000	-81,564,000	-32,836,000	-73,198,000	-18,498,000	-18,505,000	-1,004,000	-49,941,000	-2,537,000			0	-2,000	-2,016,000	-12,271,000	-12,673,000	-9,662,000	-7,494,000	-5,926,000	-38,753,000	-975,000	-24,414,000	-16,090,000	-46,215,000	-11,974,000	0	-7,653,000	-44,811,000	-3,491,000	-20,021,000	-15,691,000
proceeds from maturities and redemption of marketable securities	114,340,000	104,535,000		150,807,000	147,448,000	154,265,000
purchases of property and equipment	-1,452,000	-3,928,000	-3,478,000	-1,346,000	-779,000	-749,000	-1,723,000	-347,000	-751,000	-1,283,000	-1,587,000	-1,281,000	-2,913,000	-1,358,000	-3,036,000	-3,629,000	-1,065,000	-1,747,000	-769,000	-265,000	-686,000	-2,352,000	-1,831,000	-9,187,000	-7,501,000	-3,882,000	-1,349,000	-1,199,000	-742,000	-897,000	-295,000	-132,000	-8,000	-234,000	-1,241,000	-1,600,000	-2,305,000	-2,611,000	-2,724,000	-2,578,000	-1,050,000	-618,000					-313,000	-488,000	-293,000	-535,000	-1,204,000	-324,000	-471,000	-932,000	-564,000	-159,000	-278,000	-141,000	-287,000	-94,000	-433,000	394,000	71,000	-378,000	-505,000	435,000	230,000	444,000	-1,374,000	-3,398,000				-711,000	-647,000			-39,000	-110,000	-89,000	-282,000	-81,000	-209,000	-1,190,000
net cash from investing activities	94,792,000	6,910,000	23,366,000	-15,465,000	-28,767,000	2,831,000	-20,242,000	-106,074,000	24,722,000	-52,334,000	-32,967,000	-119,047,000	52,502,000	-216,483,000	54,938,000	45,672,000	-63,752,000	-22,633,000	14,342,000	-2,054,000	-49,383,000	10,563,000	24,851,000	-40,219,000	-42,027,000	14,613,000	44,412,000	43,564,000	27,175,000	-59,685,000	6,057,000	-82,348,000	-25,401,000	-7,011,000	28,122,000	25,981,000	11,394,000	20,752,000	-36,552,000	-63,507,000	24,785,000	-10,522,000	37,111,000	25,862,000	12,892,000	14,732,000	-102,568,000	6,660,000	8,205,000	36,351,000	4,583,000	1,442,000	-39,375,000	-6,343,000	-48,722,000			17,000,000			-28,790,000	394,000	1,700,000	7,195,000	7,745,000	3,235,000	1,634,000	7,125,000	7,728,000	13,629,000	-20,813,000	21,592,000	-18,028,000	13,652,000	-29,248,000	7,264,000	-13,990,000	15,594,000	-35,104,000	21,282,000	-7,658,000	2,773,000	-49,846,000	-1,190,000
financing activities
proceeds from issuance of convertible notes	0	39,708,000													0	0
payment for debt issuance costs	-562,000	-3,938,000
payments for debt extinguishment	0	-80,938,000
proceeds from unwind of capped call options	0	46,554,000
payments for repurchase of common stock	-71,170,000	-29,465,000
proceeds from exercise of stock options	235,000	6,503,000		1,871,000	419,000	1,635,000																																														446,000	272,000	1,071,000			0	65,000		28,000	40,000	3,000	9,000	0			0	0	0	5,000		0	0	22,000
proceeds from employee stock purchase plan	0	835,000	0	856,000	0	904,000	0	758,000	0	777,000	1,000	720,000	0	710,000	0	458,000	0	383,000	0	361,000	0	311,000	0	158,000	0	407,000	0	339,000	0	255,000	1,000	137,000	0	155,000	-1,000	355,000	0	261,000	0	188,000	0	103,000	0	60,000	1,000	69,000	0	77,000	0	147,000	0	179,000	0	128,000	0	92,000	0	40,000	0	30,000	0	42,000	0	35,000	0	37,000	0	68,000	0	136,000	0	78,000	0	71,000	0	57,000	0	57,000	-1,000	49,000	0	66,000
payments for taxes related to net share settlement of restricted and performance stock units	-421,000	-11,141,000
net cash from financing activities	-71,918,000	-31,882,000	-98,875,000	2,476,000	-1,415,000	-4,203,000	1,776,000	2,994,000	-294,000	-3,090,000	153,000	8,057,000	1,028,000	10,287,000	14,816,000	5,322,000	3,335,000	32,303,000	66,000	1,412,000	93,482,000	14,539,000	0	65,744,000	345,000	88,262,000	6,000	359,000	-123,000	98,829,000	18,078,000	81,712,000	58,665,000	29,387,000	-216,000	387,000	24,000	336,000	300,000	153,006,000	20,514,000	139,000	9,758,000	60,000	14,000	69,000	125,290,000	76,000	20,000	15,000	-14,178,000	930,000	70,037,000	2,253,000	67,054,000	4,787,000	18,660,000	939,000	43,364,000	2,122,000	41,229,000	916,000	19,708,000	2,310,000	4,000	37,000	0	-749,000	0	2,141,000	2,000,000	3,578,000	30,000,000	74,000	45,070,000	219,000	17,554,000	57,000	33,157,000	384,000	66,000	98,000	228,000	-256,000
effect of exchange rate changes on cash and cash equivalents, and restricted cash	1,100,000	458,000	-960,000	363,000	-64,000	-201,000	479,000	-305,000	-1,000	151,000
net increase in cash and cash equivalents, and restricted cash
cash and cash equivalents, and restricted cash at beginning of period	0	96,154,000		0	0	150,556,000		0	0	202,211,000
cash and cash equivalents, and restricted cash at end of period	47,405,000	52,001,000		6,841,000	-19,533,000	132,304,000		-72,256,000	52,473,000	174,560,000
supplemental disclosure of cash flow information
cash paid during the period for income taxes	1,737,000	413,000		1,614,000	2,014,000	949,000		703,000	678,000	32,000		279,000	422,000	87,000
cash paid during the period for interest	503,000	1,518,000		0				0				0				4,912,000	-2,243,000	4,296,000		4,392,000	4,345,000	3,412,000		3,415,000	3,360,000	1,940,000		1,930,000	1,900,000	813,000
non-cash investing and financing activities:
purchases of property and equipment, not yet paid	-346,000	2,046,000	961,000	188,000	219,000	355,000	-405,000	164,000	-386,000	926,000	42,000	-241,000	-793,000	2,007,000	-970,000	-570,000	1,720,000	411,000	-3,000	240,000	-284,000	408,000	-437,000	-3,785,000
net decrease in cash and cash equivalents, and restricted cash		-44,153,000	-23,458,000			-18,252,000				-27,651,000
inventory write-off											19,803,000
amortization of premiums (accretion of discounts) on marketable securities
change in fair value of warrant liability											0	0	0	-1,801,000	-19,222,000	45,121,000	-2,097,000	25,552,000	76,000	-21,245,000	25,655,000	-8,610,000
gain on sale of assets							0				0	0			0				0
prepaid manufacturing											12,727,000	41,750,000	83,853,000	21,325,000	-49,892,000	-73,465,000	-3,656,000	-3,219,000
other assets			-312,000	-777,000	-219,000	118,000	-160,000	27,000	26,000	677,000	26,000	26,000	84,000	-49,000	225,000	215,000	-170,000	-95,000	-335,000	-57,000	120,000	43,000	165,000	-1,710,000	1,305,000	1,872,000	-1,142,000	-1,730,000	-837,000	3,000		-1,017,000																																			6,000	26,000	-31,000	-80,000	-96,000	210,000	-2,000	1,157,000	-6,000	-2,000				0	-412,000	402,000		4,000
cepi accrual											0	368,000	0	-21,478,000
deferred revenue											-87,395,000	-104,603,000	-121,205,000	-36,661,000	-8,724,000	229,031,000	13,005,000	78,340,000	16,500,000																																																																	-250,000
proceeds from maturities and redemptions of marketable securities											86,250,000	83,250,000	117,700,000	35,250,000	57,975,000	48,300,000	30,225,000	51,130,000	30,915,000	43,250,000	36,500,000	37,900,000
proceeds from sale of assets, net of transaction costs											0				0				3,992,000
proceeds from warrants exercises													0	8,455,000	13,556,000	882,000
proceeds from exercise of stock options and/or release of restricted stock awards							2,021,000	2,722,000	1,378,000	239,000				1,122,000
payments for taxes related to net share settlement of rsus							-245,000	-486,000	-1,672,000	-4,106,000
cash and cash equivalents, and restricted cash at beginning of year
cash and cash equivalents, and restricted cash at end of year
cash paid during the year for income taxes
cash paid during the year for interest																																							0	287,000	249,000	184,000
reclassification of contract asset from other current assets to other assets							0	0	0	71,307,000
reclassification of cepi accrual to cepi accrual long-term							0	0	0	-60,337,000
advance payments forgiven per cepi-bio e assignment agreement							0	0
right-of-use assets obtained in exchange for operating lease liabilities																							1,522,000	4,297,000	0	34,807,000
proceeds from sale of assets
payments for taxes related to net share settlement of restricted stock units				-251,000	-1,834,000	-6,742,000
right-of-use assets obtained in exchange of operating lease liabilities								431,000	623,000	278,000
proceeds from issuances of common stock
purchases of capped call options															0	0
repayment of long-term debt															0	0
amortization of right-of-use assets and loss on disposal of property and equipment								755,000	693,000	642,000		600,000	901,000	743,000
accrued liabilities and other liabilities								8,943,000	7,413,000	-5,001,000		3,574,000	16,972,000	-39,589,000		62,330,000	10,604,000	-2,847,000		10,023,000	373,000	-3,728,000		-3,777,000	4,304,000	-7,878,000
proceeds from maturities of marketable securities								117,782,000	99,703,000	134,250,000														41,775,000	44,610,000	54,700,000	71,757,000	47,250,000	73,635,000	91,815,000	41,340,000	17,423,000	23,000,000	37,875,000	34,090,000	51,500,000	50,750,000	84,420,000	47,190,000	48,335,000	25,835,000	8,750,000	37,571,000	33,706,000	36,845,000	28,949,000	41,216,000	26,194,000	24,571,000	50,340,000	42,302,000	57,000,000	42,660,000	27,425,000	25,054,000	18,308,000	16,222,000	18,145,000	19,000,000				0	6,500,000	9,250,000	13,750,000	12,501,000	15,000,000	15,150,000	16,750,000	18,100,000	21,000,000
gain on disposal of property and equipment and from lease termination																				0	0	-76,000
realized gain on available-for-sale securities																			-1,000
stock compensation expense											8,727,000	8,613,000	7,929,000	7,646,000	6,162,000	5,376,000	5,024,000	4,723,000	3,516,000	4,102,000	4,088,000	1,778,000	5,189,000	4,748,000	9,349,000	6,170,000	6,343,000	6,046,000	6,290,000	4,799,000	4,073,000	3,660,000	3,363,000	3,821,000	4,096,000	3,662,000	3,124,000	3,244,000	2,814,000	2,630,000	1,918,000	1,954,000					1,493,000	2,845,000	3,736,000	4,266,000
cost of sales - amortization of intangible assets																			0	0	202,000	2,298,000	2,323,000	2,324,000	2,297,000	2,273,000	2,324,000	3,823,000	2,298,000	2,417,000
tenant improvements provided by the landlord																			229,000	0	0	908,000	360,000	3,411,000
acquisition of technology licenses																			0	0	0	-7,000,000	0	0	0	-7,000,000	0	-1,500,000	0	-9,500,000
proceeds from sales of marketable securities																			10,008,000																																																0	-1,000	0	4,047,000
proceeds from exercise of stock options and release of restricted stock awards											152,000	7,337,000
amortization of premium (accretion of discounts) on marketable securities																73,000	148,000	221,000
long-term deferred revenue																-38,981,000
proceeds from issuance of common stock																0	0	28,156,000		840,000	93,468,000	14,229,000		51,999,000	326,000	13,623,000						80,987,000	58,665,000	29,535,000						163,686,000
proceeds from warrants exercised
effect of exchange rate changes on cash, cash equivalents and restricted cash												-1,098,000	-523,000	-134,000	-418,000	-467,000	185,000	-731,000	731,000	675,000	313,000	-225,000	345,000	-485,000	148,000	-192,000	-155,000	-67,000	-477,000	217,000
net increase in cash, cash equivalents and restricted cash												-50,528,000	69,658,000	-256,773,000	189,833,000	116,738,000	50,556,000	46,971,000			22,591,000	-1,989,000	2,184,000	3,063,000	-77,895,000	62,781,000	10,633,000	9,984,000	-7,352,000	9,489,000
cash, cash equivalents and restricted cash at beginning of period												0	0	436,408,000		0	0	32,310,000		0	0	40,100,000		0	0	49,967,000		0	0	27,213,000
cash, cash equivalents and restricted cash at end of period												-50,528,000	69,658,000	179,635,000		116,738,000	50,556,000	79,281,000		-27,788,000	22,591,000	38,111,000		3,063,000	-77,895,000	112,748,000		9,984,000	-7,352,000	36,702,000
right-of-use assets obtained in exchange of lease liabilities												708,000	594,000	1,173,000
remeasurement of operating lease right-of-use assets for lease modification
(accretion of discounts) amortization of premium on marketable securities													-317,000	-181,000
proceeds from long-term debt																							0	0	0	74,250,000	0	0	0	99,000,000
proceeds from issuances of preferred stock
proceeds from exercise of stock options and restricted stock awards															1,260,000	3,982,000				211,000																32,000	24,000	75,000	294,000	128,000	99,000	10,000	36,000	0			82,000	0	20,000	10,000
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
proceeds allocated to warrant liability at issuance																							0
interest expense
proceeds from exercise of warrants																		3,377,000																					6,000	-6,000	202,000	26,000										300,000	151,000	1,054,000		0
proceeds (tax withholding) from exercise of stock options and restricted stock awards																		387,000					0	1,000
(gain) loss on disposal of property and equipment and from lease termination
non-cash acquisition of technology license																											0	0	0	12,773,000
proceeds from issuance of preferred stock
net decrease in cash, cash equivalents and restricted cash
(tax withholding) from exercise of stock options and restricted stock awards																						-1,000
gain on disposal of property and equipment																																-8,000	-3,000	-21,000										0	-4,000	-20,000	14,000	0																												0	0	-50,000
accretion of discounts and amortization of premiums on marketable securities																															-89,000	-69,000	-25,000	-10,000	23,000	32,000	48,000	75,000		162,000
reversal of deferred rent upon lease amendment																															0	0
accrued liabilities and other long-term liabilities
release of accrual for litigation settlement and insurance recovery																															925,000	0	0	4,050,000
revaluation of warrant liability
disposal of fully depreciated property and equipment																								8,437,000	130,000	851,000	0	157,000	5,000	37,000					1,194,000	2,000	4,000	1,154,000	1,265,000	167,000	0	4,000	166,000	11,000	390,000	274,000	78,000	0	7,000	1,000	140,000	10,000	14,000	5,000				836,000					308,000	52,000	63,000	792,000					212,000	2,000	6,000	18,000	140,000
tax withholding from exercise of stock options and restricted stock awards																										-18,000			-123,000	-426,000
write-off of assets in progress
cash-settled portion of stock compensation expense
accrued liabilities and other long term liabilities																											6,433,000	4,834,000	1,054,000	276,000	4,472,000	390,000	-301,000	-1,363,000	-11,473,000	2,874,000	656,000	-3,816,000	8,653,000	2,998,000	-277,000	-2,357,000	476,000	1,117,000	4,888,000	-1,671,000	198,000	269,000	-853,000	-1,905,000	905,000	1,831,000	1,024,000	-1,844,000	830,000	191,000	-403,000	-2,785,000	-6,566,000	2,886,000	3,997,000	3,064,000		674,000	-142,000	83,000
deferred revenues																																			0	0	-1,759,000	-895,000	-7,892,000	-818,000	-929,000	-472,000	6,266,000	-1,795,000	-2,040,000	3,036,000	-1,579,000	-1,289,000	-1,014,000	-888,000	3,121,000	776,000	-1,479,000	-946,000	4,584,000	-357,000	-358,000	-357,000	-357,000	-10,357,000	-1,312,000	-691,000	-766,000	-903,000	-13,227,000	-16,948,000	5,673,000	2,505,000	-176,000	-576,000	33,438,000	233,000	-200,000	-30,000	-649,000	10,598,000				-48,000	48,000	-7,000,000
(tax withholding) proceeds from exercise of stock options and restricted stock awards																											6,000						0	-303,000
accrual for litigation settlement and insurance recovery																																			925,000	0
return of unused development funding to astrazeneca ab
milestone payment from astrazeneca ab
common stock issuance costs - cash not paid as of period end
(gain) loss on disposal of property and equipment
accretion of debt discount related to debt financing																																							0	-15,000	-49,000	-51,000
amortization of intangible assets																																																							0	0	54,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	245,000	249,000	252,000	251,000	252,000	251,000	251,000
loss on extinguishment of debt																																							0
restricted cash and other assets																																		-907,000	-4,000	16,000	-79,000	-36,000	0				852,000	4,000	-845,000	266,000	10,000	152,000	1,000	13,000	-42,000	-5,000	14,000	-83,000	-126,000	14,000	-117,000	-61,000	2,016,000	-26,000	-1,004,000	-1,024,000		-10,000	-16,000	17,000
payment of debt																																							2,000
proceeds (withholding) from exercise of stock options and restricted stock awards
effect of exchange rate changes on cash and cash equivalents																															102,000	184,000	331,000	57,000	-356,000	74,000	-62,000	92,000	-121,000	48,000	46,000	-276,000	-147,000	-209,000	-18,000	3,000
net increase in cash and cash equivalents																																			1,268,000				-58,219,000			-34,798,000	29,855,000	2,624,000	-9,718,000	3,628,000	10,931,000	-5,394,000	-7,431,000	17,417,000													11,985,000	976,000	839,000	-5,183,000	5,485,000	7,748,000	-988,000	1,565,000	-349,000	8,139,000	-6,476,000	-1,175,000	-1,797,000			8,117,000	-10,443,000	14,052,000	-6,285,000	-5,189,000	-54,924,000	-2,445,000
cash and cash equivalents at beginning of year																																															0	0	0	7,599,000
cash and cash equivalents at end of year																																															10,931,000	-5,394,000	-7,431,000	25,016,000
net change in unrealized gain on marketable securities																															-52,000	14,000	-16,000	-29,000	-15,000	-61,000	-41,000	109,000	7,000	5,000	-9,000	8,000	-37,000	-1,000	1,000	69,000	-53,000	18,000	-33,000	-8,000	16,000	59,000								-7,000
cash-settled portion of stock-based compensation expense																																				0	274,000	328,000	0	0
net decrease in cash and cash equivalents																																		-2,817,000			-14,071,000	-5,954,000														-9,880,000	14,777,000	-12,188,000				-1,482,000		-844,000	-1,027,000	-6,640,000
cash and cash equivalents at beginning of period																																0	0	24,289,000		0	0	44,812,000		0	0	49,511,000		0	0	23,122,000						0	0	31,941,000		0	0	22,453,000		0	0	36,720,000		0	0	28,103,000		0	0	14,293,000		0	0	14,154,000		0	0	8,725,000		0	0	16,590,000
cash and cash equivalents at end of period																																-17,579,000	16,203,000	21,472,000		-1,766,000	-14,071,000	38,858,000		66,545,000	21,773,000	14,713,000		2,624,000	-9,718,000	26,750,000						-9,880,000	14,777,000	19,753,000		-8,407,000	6,508,000	20,971,000		-844,000	-1,027,000	30,080,000		976,000	839,000	22,920,000		7,748,000	-988,000	15,858,000		8,139,000	-6,476,000	12,979,000		5,861,000	-6,752,000	16,842,000		14,052,000	-6,285,000	11,401,000
unoccupied facility expense																																												131,000	178,000	77,000	8,000
(withholding) proceeds from exercise of stock options and restricted stock awards
return of unused development funding to astrazeneca ab “astrazeneca”
milestone payment from astrazeneca
accretion of end of term payment related to debt financing																																									50,000	57,000
accounts receivable																																						230,000	-231,000	-506,000	252,000	-182,000	0	565,000	438,000	-103,000	532,000	-134,000	-478,000	-542,000	2,680,000	-2,401,000	91,000	8,152,000	-8,744,000	356,000	-12,000	-126,000	254,000	94,000	-197,000	-257,000	289,000	335,000	1,459,000	3,429,000	-191,000	1,841,000	-1,917,000	1,094,000	-6,660,000	528,000	116,000	936,000	-269,000	-1,175,000	197,000	271,000		-317,000	8,213,000	-5,826,000		1,028,000
accretion of discounts and amortization of premiums of marketable securities																																										171,000	167,000	214,000	236,000	264,000	231,000	162,000	250,000	280,000	328,000	332,000	334,000	304,000
proceeds from long-term debt payable to hercules
loss on lease
interest associated with long-term note payable to symphony dynamo holdings llc
payment of notes payable to holdings
purchases of property and equipment, net of proceeds from asset disposals																																												-288,000	-521,000	-398,000
payment of issuance costs
proceeds from issuances of common stock and warrants, net of issuance costs																																																		-142,000
fair value adjustment of the warrant and contingent liabilities to holdings, including the impact of the anti-dilution provision associated with the common stock and warrants issued to symphony capital partners, l.p. and symphony strategic partners, llc
proceeds from issuances of warrants
interest associated with long-term note payable to holdings
payments and proceeds from issuances of common stock and warrants, net of issuance costs																																																-1,000
effect of exchange rate on cash and cash equivalents																																																125,000	33,000	-63,000	136,000	95,000	-196,000	83,000	-175,000	-155,000	38,000	74,000	-6,000	104,000	327,000	-448,000	-132,000	313,000	462,000	-408,000	-130,000	-602,000	9,000	60,000	35,000	73,000	10,000	-2,000	62,000	22,000			-1,000	0	0	-4,000
shares issued to aspire capital in conjunction with purchase agreement
shares issued in conjunction with the symphony dynamo, inc. (“sdi”) transaction
warrants issued in conjunction with the sdi transaction
gain on disposal of assets
non-cash interest associated with the note payable to holdings																																																				547,000	548,000	547,000
fair value adjustment of the warrant and contingent liabilities to holdings
proceeds from offering of common stock, net of issuance costs
(gain)/loss on disposal of assets																																																								0
proceeds from issuance of common stock, net of issuance costs																																																								4,591,000	18,653,000	834,000	43,275,000	2,064,000	42,108,000	-48,000	-33,000																				-79,000	75,000
net income attributable to dynavax																																																											-15,122,000	-4,998,000	-28,004,000	-9,184,000	-30,270,000	-9,506,000	4,110,000	5,101,000
consideration paid in excess of carrying value of the noncontrolling interest in sdi
amount attributed to noncontrolling interest in sdi																																																															-1,041,000	-1,200,000	-983,000	-1,009,000	-939,000
non-cash interest associated with long-term note payable to holdings																																																							468,000
fair value adjustment of the warrant and contingent liabilities to holdings, including the impact of the anti-dilution provision associated with the common stock and warrants issued to symphony
interest associated with deerfield financing agreement																																																															0							1,323,000
change in investments held by sdi																																																															1,629,000	1,075,000	1,016,000	1,321,000	1,576,000	1,344,000	1,446,000	2,156,000
cash acquired from the purchase of noncontrolling interest in sdi
note payable issued to holdings from purchase option exercised under the sdi collaboration
shares issued in conjunction with the sdi transaction
liability from program option exercised under the sdi collaboration																																																																								0
modification of warrants previously issued to deerfield																																																																			9,000
fair value adjustments to the common stock, warrant and contingent liability issued to holdings
accretion and amortization of marketable securities																																																								278,000	263,000	354,000	242,000	83,000
proceeds from the sale of property and equipment
proceeds from exercise of stock options and delivery of restricted stock units
disposal of fully depreciated assets																																																								0
net change in unrealized losses on marketable securities
non-cash interest associated with long-term note payable to symphony dynamo holdings llc																																																									467,000	468,000
fair value adjustment of the warrant and contingent liabilities to symphony dynamo holdings llc																																																									20,000	-3,000
net cash provided (used) by investing activities
fair value adjustment of the warrant and contingent liabilities to holdings, including the impact of the anti-dilution provision associate with the common stock and warrants issued to symphony
loan forgiveness																																																																			0
proceeds from notes payable issued to deerfield																																																																			0	0	0	2,000,000
repayment of notes payable issued to deerfield																																																																			0
non-cash interest associated with deerfield financing agreement
non-cash interest associated with note payable to holdings																																																												400,000
fair value of the common stock, warrants and contingent liability issued to holdings
net cash (used in ) provided by investing activities
fair value of the common stock, warrant, and contingent liability to holdings
interest associated with note payable to holdings																																																														399,000
change in the fair value of the warrant and contingent consideration to holdings																																																														-183,000
proceeds from issuance of common stock under equity distribution agreement, net of issuance costs																																																														919,000
accretion and amortization on marketable securities																																																															0	10,000	24,000	-30,000	-100,000	-88,000	-202,000	-331,000	-277,000	-339,000	-551,000	-688,000	-448,000	-17,000	60,000	109,000		210,000	322,000	318,000
inventory																																																																							263,000	-15,000	-2,000	11,000
accrued liabilities																																																																			-5,161,000	1,152,000	114,000	-2,234,000	900,000	1,136,000	-152,000	-954,000	3,812,000	-319,000	1,486,000	868,000		-639,000	309,000	-131,000		1,650,000
proceeds from purchase of noncontrolling interest by preferred shareholders in sdi, net of fees
non-cash activities:
note payable to holdings from purchase option exercised under the sdi collaboration
warrants issued in conjunction with the deerfield financing agreement
loss on the disposal of assets
acquired in-process research and development																																																																											0	0
realized loss on investments																																																																														23,000
cash paid for acquisition, net of cash acquired																																																																											0	0
proceeds from purchase of noncontrolling interest by shareholders in sdi, net of fees
loss on disposal of assets																																																																				23,000
interest expense associated with deerfield financing agreement																																																																				6,885,000
proceeds from the purchase of noncontrolling interest in sdi, net of fees
supplemental disclosure of non-cash flow information
warrants issued in conjunction with deerfield financing agreement
amount attributed to noncontrolling interest in symphony dynamo, inc.																																																																					-1,489,000	-1,566,000	-2,001,000	-1,621,000
realized gain on investments
interest accrued on notes receivable from stockholders																																																																															0	-4,000	-5,000	-7,000	-9,000	-9,000
purchases of investments held by sdi
exercise of stock options																																																																											1,029,000	162,000			13,000	0	-194,000	200,000
repayment of notes receivable from stockholders																																																																															8,000	335,000	60,000	32,000	221,000	0
liability from program option exercised under the sdi transaction
repurchase of common stock for exercise of stock options																																																																															0	0	0	-200,000
realized loss on sale of marketable securities																																																																												0
increase in interest payable
purchases disposal of property and equipment
proceeds from deerfield financing agreement
issuance cost associated with common stock offering																																																																								0	0	-19,000
supplemental disclosure of non-cash investing and financing activities
warrants issued in conjunction with sdi transaction
change in investments held by symphony dynamo, inc.																																																																									-26,489,000	4,754,000
(purchases) disposal of property and equipment
proceeds from purchase of noncontrolling interest by preferred shareholders in symphony dynamo, inc., net of fees																																																																												0
warrants issued in conjunction with the symphony dynamo, inc. transaction																																																																											0	0
loss attributed to noncontrolling interest in symphony dynamo, inc.																																																																										-2,016,000		-3,271,000
maturities and sales of marketable securities																																																																										25,699,000	13,250,000	18,440,000	19,019,000	23,286,000	9,817,000	24,862,000	12,645,000	18,545,000
purchases of investments held by symphony dynamo, inc.																																																																											4,364,000	1,317,000
proceeds from purchase of noncontrolling interest by shareholders in symphony dynamo, inc., net of fees
restricted cash																																																																																			0	-331,000
change in unrealized gain on marketable securities
lease incentive
conversion of preferred stock upon initial public offering
conversion of ordinary shares in dynavax asia upon initial public offering
interest accrued on notes receivable
change in unrealized loss on marketable securities																																																																												79,000
change in cumulative translation adjustment																																																																												22,000			-1,000	0	0	-4,000
disposal (purchases) of property and equipment
net increase increase in cash and cash equivalents
adjustments to reconcile net income (income) to net cash from operating activities:
amortization of stock-based compensation expense																																																																														666,000	439,000	308,000	336,000	317,000	793,000	728,000
net change in unrealized loss on marketable securities																																																																														29,000	-48,000
loss on disposal of property and equipment																																																																																			0	1,000
realized loss on investment
proceeds from issuance of ordinary shares in dynavax asia, net of issuance costs
repurchase of common stock
repurchase of common stock for notes receivable
deemed dividend upon issuance of ordinary shares of dynavax asia
conversion of ordinary shares in dynavax asia upon initial public offering.
net unrealized loss on marketable securities																																																																																	41,000	-59,000
proceeds from issuance of preferred stock, net of issuance costs
repayments of equipment financing
accretion and amortization on investments																																																																																				0
purchase of marketable securities
maturities and sale of marketable securities																																																																																				0
cash and cash equivalents at beginning of the period																																																																																				0
cash and cash equivalents at end of the period																																																																																				-2,445,000

We provide you with 20 years of cash flow statements for Dynavax Technologies stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Dynavax Technologies stock. Explore the full financial landscape of Dynavax Technologies stock with our expertly curated income statements.

The information provided in this report about Dynavax Technologies stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.